GlucoTrack's subsidiary, Lokahi Therapeutics, announced a simplified single-injection strategy for its LT-100 program, a treatment for osteoarthritis knee pain. This development significantly improves the potential marketability and patient acceptance of the drug, leading to a substantial after-hours stock surge despite recent debt restructuring and a weak overall market position.
GlucoTrack (GCTK) shares surged over 70% after its subsidiary, Lokahi Therapeutics, announced a simplified single-injection strategy for its LT-100 program, which treats osteoarthritis knee pain. This is a significant positive development because replacing 15 intradermal injections with a single subcutaneous injection dramatically improves patient convenience and compliance, making the drug far more attractive to both patients and healthcare providers. While the company also recently disclosed debt restructuring, the positive news regarding the LT-100 program overshadowed this, indicating that the market is reacting strongly to potential future revenue streams. For traders, this presents a short-term opportunity driven by positive clinical development news, but the company's overall weak market position and significant past declines suggest long-term risks remain, requiring careful monitoring of future clinical trial results and financial health.